Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edasalonexent - BioCryst Pharmaceuticals

Next Previous
Drug Profile

Edasalonexent - BioCryst Pharmaceuticals

Alternative Names: CAT-1004; Docosahexaenoic acid-sodium salicylate conjugate; Sodium salicylate-docosahexaenoic acid conjugate

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Developer BioCryst Pharmaceuticals; Sarepta Therapeutics
  • Class Amides; Anti-inflammatories; Antihyperglycaemics; Docosahexaenoic acids; Drug conjugates; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy; Dysferlinopathy; Type 2 diabetes mellitus

Most Recent Events

  • 23 Jan 2026 Astria Therapeutics has been acquired and merged into BioCryst Pharmaceuticals
  • 28 Sep 2022 Discontinued - Phase-III for Duchenne muscular dystrophy (In children) in Australia (PO)
  • 28 Sep 2022 Discontinued - Phase-III for Duchenne muscular dystrophy (In children) in Canada (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top